194 related articles for article (PubMed ID: 24158837)
1. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma.
Larkin KL; Saboo US; Comer GM; Forooghian F; Mackensen F; Merrill P; Sen HN; Singh A; Essex RW; Lake S; Lim LL; Vasconcelos-Santos DV; Foster CS; Wilson DJ; Smith JR
Br J Ophthalmol; 2014 Jan; 98(1):99-103. PubMed ID: 24158837
[TBL] [Abstract][Full Text] [Related]
2. Vitreoretinal lymphoma: changing trends in diagnosis and local treatment modalities at a single institution.
Turaka K; Bryan JS; De Souza S; Gordon AJ; Kwong HM; Ziemianski MC; Reddy R; Sell CH
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):412-7. PubMed ID: 22995952
[TBL] [Abstract][Full Text] [Related]
3. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma.
Zhou N; Xu X; Liu Y; Wang Y; Wei W
Eye (Lond); 2022 Jul; 36(7):1448-1455. PubMed ID: 34211136
[TBL] [Abstract][Full Text] [Related]
4. Combination intravitreal rituximab and methotrexate for massive subretinal lymphoma.
Yeh S; Wilson DJ
Eye (Lond); 2010 Oct; 24(10):1625-7. PubMed ID: 20706284
[No Abstract] [Full Text] [Related]
5. Intravitreal rituximab monotherapy for management of eyes with vitreoretinal lymphoma: initial experience from India.
Rishi P; Manchegowda PT; Gondhale HP; Rishi E; Das K; Krishnakumar S; Raja T; Biswas J
Int Ophthalmol; 2021 Jul; 41(7):2495-2504. PubMed ID: 33730314
[TBL] [Abstract][Full Text] [Related]
6. Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients.
Zhou X; Zhou X; Shi H; Lai J; Wang Q; Li Y; Chen K; Li Q; Zhou Q; Cao X; Chen B; Xiao J
BMC Ophthalmol; 2020 May; 20(1):189. PubMed ID: 32397978
[TBL] [Abstract][Full Text] [Related]
7. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma.
Salomão DR; Pulido JS; Johnston PB; Canal-Fontcuberta I; Feldman AL
JAMA Ophthalmol; 2013 Sep; 131(9):1151-8. PubMed ID: 23744124
[TBL] [Abstract][Full Text] [Related]
8. Intraocular (vitreoretinal) lymphoma following primary testicular lymphoma.
Grange LK; Jacobs-El N; Wiley HE; Kurup S; Chan CC; Sen HN
Can J Ophthalmol; 2013 Aug; 48(4):e95-7. PubMed ID: 23931497
[No Abstract] [Full Text] [Related]
9. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.
Frenkel S; Hendler K; Siegal T; Shalom E; Pe'er J
Br J Ophthalmol; 2008 Mar; 92(3):383-8. PubMed ID: 18303160
[TBL] [Abstract][Full Text] [Related]
10. Multimodal imaging characteristics in eyes with vitreoretinal lymphoma treated with intravitreal rituximab.
Rishi P; Maitra P; Das K; Rishi E; Manchegowda PT
Int Ophthalmol; 2021 Aug; 41(8):2711-2722. PubMed ID: 33834345
[TBL] [Abstract][Full Text] [Related]
11. Retinal and Choroidal Changes of Vitreoretinal Lymphoma from Active to Remission Phase after Intravitreal Rituximab.
Cicinelli MV; Marchese A; Miserocchi E; Giuffré C; Berchicci L; Querques G; Bandello F; Modorati GM
Ocul Immunol Inflamm; 2020 May; 28(4):637-646. PubMed ID: 31393199
[TBL] [Abstract][Full Text] [Related]
12. INTRAVITREAL MELPHALAN INJECTION AS A SECOND-LINE LOCAL THERAPY IN VITREORETINAL LYMPHOMA: Case Series.
Guneri Beser B; Demirci H
Retina; 2024 Feb; 44(2):353-359. PubMed ID: 37883576
[TBL] [Abstract][Full Text] [Related]
13. Clinical review: treatment of vitreoretinal lymphoma.
Pe'er J; Hochberg FH; Foster CS
Ocul Immunol Inflamm; 2009; 17(5):299-306. PubMed ID: 19831557
[TBL] [Abstract][Full Text] [Related]
14. Use of intravitreal rituximab and methotrexate in vitreoretinal lymphoma.
Rahhal-Ortuño M; Udaondo-Mirete P; Fernández-Santodomingo AS; Díaz-Llopis M
Eur J Ophthalmol; 2022 Jan; 32(1):NP199-NP202. PubMed ID: 32985253
[TBL] [Abstract][Full Text] [Related]
15. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
[TBL] [Abstract][Full Text] [Related]
16. Primary Vitreoretinal Lymphoma Therapy Monitoring: Significant Vitreous Haze Reduction After Intravitreal Rituximab.
Kakkassery V; Heindl LM; Rokohl AC; Chronopoulos A; Schutz JS; Ranjbar M; Schargus M; Böker A; Winterhalter S; Stübiger N
Neurosignals; 2021 May; 29(S1):1-7. PubMed ID: 33945240
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse.
Klimova A; Heissigerova J; Rihova E; Brichova M; Pytlik R; Spicka I; Mrazova K; Karolova J; Svozilkova P
Br J Ophthalmol; 2018 Nov; 102(11):1579-1585. PubMed ID: 29378728
[TBL] [Abstract][Full Text] [Related]
18. Changes in choroidal vascular structure from vitreoretinal lymphoma and the intraocular cytokine level associated with clinical resolution after intravitreal methotrexate treatment.
Kim RY; Park JH; Kim M; Park YG; Cho SG; Park YH
PLoS One; 2021; 16(11):e0260469. PubMed ID: 34813633
[TBL] [Abstract][Full Text] [Related]
19. Secondary Vitreoretinal Lymphoma Masquerading as Acute Retinal Necrosis.
Ryan ME; Shantha JG; Grossniklaus HE; Yeh S
Ophthalmic Surg Lasers Imaging Retina; 2015; 46(10):1048-50. PubMed ID: 26599249
[TBL] [Abstract][Full Text] [Related]
20. Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate.
Jiang T; Gu J; Liu S; Chang Q
BMC Ophthalmol; 2022 Sep; 22(1):375. PubMed ID: 36127675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]